uniQure Surges After FDA Reverses Course on Huntington's Gene Therapy Filing

uniQure shares surged after the company said the FDA will let it pursue a Biologics License Application for AMT-130, its Huntington’s disease gene therapy, using existing Phase 1/2 data and a three-year analysis rather than requiring a new placebo-controlled trial.

The move marks a sharp reversal from the agency’s November 2025 position, when the FDA said the early- and mid-stage data were not adequate to support a filing. That earlier ruling had left investors expecting a longer and riskier development path for the program.

Market reports said the stock jumped about 78% to 81% on June 17, reaching roughly $48 to $49 intraday or at the close. Barron’s reported that shares rose 81% to $48.77, while Investor’s Business Daily and The Wall Street Journal also described a near-80% rally tied to the FDA decision.

What Changed

According to uniQure’s account and the market reporting, the FDA is now willing to review the company’s filing without forcing it to run a new placebo-controlled trial first. The key change is that uniQure can rely on its Phase 1/2 data package together with a three-year analysis.

That shift matters because the path to approval had appeared blocked only months earlier. The FDA’s prior view had raised the bar significantly for AMT-130, a gene therapy aimed at a rare and difficult-to-study disease.

The latest development does not guarantee approval. It does, however, reopen a regulatory route that had looked much narrower in late 2025.

Why Investors Repriced The Stock

The market reaction was immediate because the FDA reversal removes one of the biggest uncertainties hanging over AMT-130. For a biotech company, the difference between needing a new trial and being allowed to file on existing data can transform the timeline, cost and odds of success.

Barron’s reported that Cantor Fitzgerald upgraded uniQure to Buy and raised its price target to $61 from $18 after the news. That move reinforced the view that the latest FDA decision materially improved the program’s approval prospects.

The stock move also reflects the importance of AMT-130 as uniQure’s lead asset. Investors have been watching the therapy closely because it is one of the few high-profile gene-therapy programs targeting Huntington’s disease.

The Regulatory Timeline

The chronology helps explain why the news was so dramatic.

On November 3, 2025, reporting said the FDA had concluded uniQure’s Phase 1/2 data were not adequate for a BLA submission. That created a major obstacle for the program and raised questions about whether the company would need additional controlled data before it could file.

On June 17, 2026, uniQure said the FDA had cleared it to submit a BLA for AMT-130. Later that day, Barron’s published its market report, Investor’s Business Daily reported the FDA would let the company refile using three-year clinical data, and The Wall Street Journal noted that the agency had reversed course and removed the immediate need for a new placebo-controlled trial before filing.

Taken together, those reports describe a clear pivot from regulatory resistance to a reopened filing path.

Why AMT-130 Matters

AMT-130 is uniQure’s investigational gene therapy for Huntington’s disease, a rare inherited neurodegenerative disorder with no approved disease-modifying treatment.

That makes the program especially important to patients, advocates and investors. Huntington’s disease is difficult to study, patient numbers are limited, and meaningful clinical development can be slow. A workable FDA path for AMT-130 would therefore be a significant milestone, not just for uniQure but for the broader gene-therapy field.

uniQure is a Dutch biopharmaceutical company focused on gene therapies. It previously won FDA approval for Hemgenix, a hemophilia B gene therapy commercialized by CSL Behring, which gives the company some precedent in navigating the U.S. regulatory process.

What Happens Next

The company still needs to complete the filing process and work through the FDA review itself. The latest shift improves the path to submission, but it does not end the regulatory process.

One unresolved issue is the design of any confirmatory or backup study. Research notes that uniQure and the FDA still need to align on that question, even after the agency’s reversal.

Investors will also watch for a formal filing timeline and for any FDA feedback after submission. Those details will matter for judging how quickly AMT-130 can move toward a decisive review.

There is also a broader question hanging over the story: whether this is a program-specific decision or a sign of a more flexible FDA stance toward certain hard-to-study rare-disease therapies.

For now, the immediate takeaway is straightforward. The FDA’s reversal has materially improved uniQure’s regulatory outlook, and that is why the stock moved violently on June 17.